Recall Radar · 美国食品召回雷达
FDA Food Enforcement · Other / 其他Ferrous Sulfate Tablets 325 mg, 100 count bottles, Nutritional Supplement. Label reads in part "OPTIMUM *** FERROUS SULFATE 325 * mg 5 Grain *** Gluten Free Dietary Supplement *** Manufactured & Distributed by: Magno-Humphries Labs Tigard, OR 97223 U.S.A. *** *325 mg calculated as Ferrous Sulfate Heptahydrate. ***" UPC 0 43292 56306 0 There are 72 bottles per shipping case and most product is shipped by case.
Recall number / 召回编号
F-1304-2013
Classification / 风险等级
Other / 其他
Published / 发布时间
2013-04-17
Recalling firm / 召回企业
Magno Humphries Inc
Product description / 产品描述
Ferrous Sulfate Tablets 325 mg, 100 count bottles, Nutritional Supplement. Label reads in part "OPTIMUM *** FERROUS SULFATE 325 * mg 5 Grain *** Gluten Free Dietary Supplement *** Manufactured & Distributed by: Magno-Humphries Labs Tigard, OR 97223 U.S.A. *** *325 mg calculated as Ferrous Sulfate Heptahydrate. ***" UPC 0 43292 56306 0 There are 72 bottles per shipping case and most product is shipped by case.
Product code / 产品代码
Not provided in the official record
Code information / 批次与代码信息
Product code -L6430-100-01(L is designate label, 6430 is the firm's internal product code, 100 is for 100 count and 01 stands for Optimum label, and 0 is the firm's version number. All of these products have the same label code, however; they have different lot numbers. Lot Numbers: 343617, 343718, 343739, 343753, 343814, 343888, and 343959. Expiration dates 11/15, 12/15, 12/15, 12/15, 12/15, 1/16 and 1/16 respectively (expiration dates are month and year) The lot number and expiration date is stamped on the bottom of the bottles.
Product quantity / 产品数量
40369 bottles
Distribution / 销售地区
Distributed to only one consignee with several locations nationwide.
Reason for recall / 召回原因
The firm found minute pieces of blue material identified by their raw material supplier as polypropylene, a relatively inert plastic.
Open official source ↗ / 打开官方来源
Last synchronized: 2026-08-09. Recall Radar does not replace agency guidance.